These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24247138)

  • 1. Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.
    Richter SS; Diekema DJ; Heilmann KP; Dohrn CL; Crispell EK; Riahi F; McDanel JS; Satola SW; Doern GV
    Antimicrob Agents Chemother; 2014; 58(2):740-5. PubMed ID: 24247138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
    Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
    J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
    J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
    BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
    Ozmen Capin BB; Tekeli A; Karahan ZC
    Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
    [No Abstract]   [Full Text] [Related]  

  • 6. Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.
    Souli M; Karaiskos I; Galani L; Maraki S; Perivolioti E; Argyropoulou A; Charissiadou A; Zachariadou L; Tsiplakou S; Papaioannou V; Tsorlini H; Katsifa H; Baka V; Pantazi P; Paschali A; Kyratsa A; Trikka-Graphakos E; Giannopoulou P; Vogiatzakis E; Moraitou H; Papadogeorgaki H; Avgerinou H; Panagea T; Pantazatou A; Petinaki E; Stamatopoulou G; Toutouza M; Karatzoglou I; Kontopoulou K; Orfanidou M; Karantani I; Fytas P; Tzanetou K; Platsouka E; Kazila P; Chli A; Statiri N; Giamarellou H
    Infect Dis (Lond); 2016 Apr; 48(4):287-292. PubMed ID: 26635179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.
    Cheng X; Ma L; Wang Y; Sun W; Su J
    Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116180. PubMed ID: 38183897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
    Richter SS; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Kroeger JS; Biek D; Critchley IA; Diekema DJ; Doern GV
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4154-60. PubMed ID: 21709080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
    Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE
    J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.
    van Hal SJ; Wehrhahn MC; Barbagiannakos T; Mercer J; Chen D; Paterson DL; Gosbell IB
    J Clin Microbiol; 2011 Apr; 49(4):1489-94. PubMed ID: 21270232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
    Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
    J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
    Sun W; Chen H; Liu Y; Zhao C; Nichols WW; Chen M; Zhang J; Ma Y; Wang H
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3642-9. PubMed ID: 19546358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of the VISA and hVISA Presence in Methicillin-Resistant Staphylococcus aureus Isolates by Various Methods].
    Uçar Ş; Duman Y; Tanrıverdi ES; Tekerekoğlu MS; Otlu B
    Mikrobiyol Bul; 2022 Oct; 56(4):593-605. PubMed ID: 36458707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.